sirolimus是什么药物？

What is Leipaming used to treat? Sirolimus was approved by the FDA on May 30, 2007 for the treatment of advanced kidney disease and kidney transplantation. It has now entered clinical phase 4 for the treatment of mantle cell lymphoma.

As mentioned in the efficacy and role of rapamycin sirolimus, rapamycin sirolimus is suitable for patients receiving kidney transplants to prevent organ rejection. Recommended for use in combination with cyclosporine and corticosteroids. Sirolimus, the main component of rapamycin sirolimus, inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies.

In cells, rapamycin sirolimus binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian sirolimus BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from the G1 phase to the S phase in the cell cycle.

Sirolimus is an oral medication and is recommended to be taken once daily. It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose that should be taken for the first time is three times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day.

Adverse reactions of rapamycin sirolimus are common (incidence >10% according to International Council of Medical Organization frequency classification): lymphocele, peripheral edema, abdominal pain, diarrhea, hypokalemia, increased lactate dehydrogenase, acne, urinary tract infection; common at higher doses: anemia, hypercholesterolemia, thrombocytopenia, hypertriesteremia (hyperlipidemia). Store in a cool, dry, dark environment.

The above are the indications of rapamycin that we provide you. If you have any other questions, please consult the medical companion passenger service.